Health & ScienceNews Briefs
MobileODT EVA VisualCheck AI Technology for Cervical Cancer Screening. Photo: PRNewsfoto/MobileODT
Israeli femtech company MobileODT, the developer of a mobile, AI-based cervical cancer screening test, has embarked on a large-scale project in the Dominican Republic to screen women for the disease using its Enhanced Visual Assessment System (EVA System) digital colposcope.
Cervical cancer is a preventable and treatable disease mainly caused by the Human papillomavirus (HPV), a common virus transmitted through sexual activity. The World Health Organization says it’s the fourth most common cancer in women, with over 550,000 cases and more than 300,000 deaths recorded every year, a majority in low and middle-income countries.
Results for
Israeli AI FemTech solution secures prestigious US cancer grant to advance women s health
The Israeli FemTech startup earns a prestigious grant from the National Cancer Institute, as an innovator in the battle against cancer. Dor Schwartz / 25 Jan 2021 • 2 min read
MobileODT, an Israeli FemTech startup focusing on AI-powered cervical screening, has caught the eye of the US National Cancer Institute (NCI), with the NCI awarding Mobile ODT with a $2.3 million grant. The Small Business Innovation Research Authority grant is given by the NCI to companies that are technologically and clinically reducing the suffering from cancer. We are honored to receive such a prestigious grant, especially from National Cancer Institute. It s a recognition of the value that our technology is bringing to women s health, said Leon Boston, MobileODT CEO.
Share this article
Share this article
TEL AVIV, Israel, Jan. 20, 2021 /PRNewswire/ MobileODT, a FemTech company producing the latest digital innovation in cervical screening, has been awarded a prestigious Small Business Innovation Research Authority grant of $2.3 million. This grant is presented by the United States National Cancer Institute (NCI) to leading companies that are technologically and clinically advanced to support the NCI s goal of reducing suffering and death due to cancer. This grant is a tribute to the groundbreaking advances of MobileODT as an innovative company commercializing a novel cervical cancer screening technology utilizing complex machine learning (ML) and artificial intelligence (AI) algorithms. The company s technology offers an alternative screening modality to the current standard-of-care with significantly improved accuracy. It allows for a broader range of physicians, to perform cervical cancer screening, while defining the actual status of the pa